The tyrosine kinase inhibitor imatinib mesylate (IM) has proved a major advance in the management of patients with chronic myeloid leukaemia (CML) but about 15% of patients do not achieve complete cytogenetic responses (CCyR) (primary resistance) and a further 15-20% of those who do achieve CCyR eventually lose their response (secondary resistance). The best characterised mechanism of resistance is the expansion of a Ph-positive clone bearing an amino-acid substitution in the BCR-ABL1 kinase domain (KD). We screened over 300 CML patients for KD mutations and demonstrated that detection of a mutation after achieving CCyR is an independent prognostic factor for the loss of response and disease progression regardless of the level of mutant clo...
PURPOSE: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with ...
Purpose of reviewImatinib, which was the first targeted therapy for patients with chronic myeloid le...
Chronic myeloid leukaemia (CML) is a chronic myeloproliferative disease that is characterized by the...
The tyrosine kinase inhibitor imatinib mesylate (IM) has proved a major advance in the management of...
Chronic Myeloid Leukaemia (CML) is a myeloproliferative disorder whose hallmark is represe...
Chronic myeloid leukaemia (CML) is a chronic myeloproliferative disease that is characterized by the...
Chronic myeloid leukemia (CML) is caused by the formation of the BCR-ABL fusion protein as a result ...
Imatinib has undoubtedly revolutionised the treatment of chronic myeloid leukaemia (CML) and hence h...
Chronic myeloid leukaemia (CML) is a molecularly defined disease. The BCR-ABL fusion occurs in all c...
The treatment of chronic myelogenous leukemia (CML) has been revolutionized by the development of th...
In the face of competing first-line treatment options for CML, early prediction of prognosis on imat...
Abstract: CML is a hematopoietic stem cell disease which is characterized by the presence of Philade...
Chronic Myelogenous Leukemia (CML) is a hematopoietic cancer caused by the formation of the Philadel...
Purpose: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with ...
Previous clinical trials with the tyrosine kinase inhibitor imatinib in chronic-phase Philadelphia c...
PURPOSE: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with ...
Purpose of reviewImatinib, which was the first targeted therapy for patients with chronic myeloid le...
Chronic myeloid leukaemia (CML) is a chronic myeloproliferative disease that is characterized by the...
The tyrosine kinase inhibitor imatinib mesylate (IM) has proved a major advance in the management of...
Chronic Myeloid Leukaemia (CML) is a myeloproliferative disorder whose hallmark is represe...
Chronic myeloid leukaemia (CML) is a chronic myeloproliferative disease that is characterized by the...
Chronic myeloid leukemia (CML) is caused by the formation of the BCR-ABL fusion protein as a result ...
Imatinib has undoubtedly revolutionised the treatment of chronic myeloid leukaemia (CML) and hence h...
Chronic myeloid leukaemia (CML) is a molecularly defined disease. The BCR-ABL fusion occurs in all c...
The treatment of chronic myelogenous leukemia (CML) has been revolutionized by the development of th...
In the face of competing first-line treatment options for CML, early prediction of prognosis on imat...
Abstract: CML is a hematopoietic stem cell disease which is characterized by the presence of Philade...
Chronic Myelogenous Leukemia (CML) is a hematopoietic cancer caused by the formation of the Philadel...
Purpose: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with ...
Previous clinical trials with the tyrosine kinase inhibitor imatinib in chronic-phase Philadelphia c...
PURPOSE: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with ...
Purpose of reviewImatinib, which was the first targeted therapy for patients with chronic myeloid le...
Chronic myeloid leukaemia (CML) is a chronic myeloproliferative disease that is characterized by the...